Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 3, 2015, Pages 541-551

  Tsang, Chi Man ^a   Cheung, Kenneth Chat Pan ^a   Cheung, Yuk Chun ^a   Man, Kwan ^a   Lui, Vivian Wai Yan ^a   Tsao, Sai Wah ^a   Feng, Yibin ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti cancer; Berberine; Hepatocellular carcinoma; Id 1; Metastasis

Indexed keywords

BERBERINE; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ID1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN SECRETION; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; LIVER NEOPLASMS; LUNG NEOPLASMS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS;

ANIMALS; BERBERINE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920592679     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.12.004     Document Type: Article

References (33)

1. Grycova L., Dostal J., Marek R. Quaternary protoberberine alkaloids. Phytochemistry 2007, 68:150-175.
2. Tang J., Feng Y., Tsao S., Wang N., Curtain R., Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J. Ethnopharmacol. 2009, 126:5-17.
3. Tsang C.M., Lau E.P., Di K., Cheung P.Y., Hau P.M., Ching Y.P., Wong Y.C., Cheung A.L., Wan T.S., Tong Y., Tsao S.W., Feng Y. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int. J. Mol. Med. 2009, 24:131-138.
4. Wang L., Cao H., Lu N., Liu L., Wang B., Hu T., Israel D.A., Peek R.M., Polk D.B., Yan F. Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PLoS One 2013, 8:e56666.
5. Eom K.S., Hong J.M., Youn M.J., So H.S., Park R., Kim J.M., Kim T.Y. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol. Pharm. Bull. 2008, 31:558-562.
6. Kim S., Oh S.J., Lee J., Han J., Jeon M., Jung T., Lee S.K., Bae S.Y., Kim J., Gil W.H., Kim S.W., Lee J.E., Nam S.J. Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2013, 32:1541-1550.
7. Lin S., Tsai S.C., Lee C.C., Wang B.W., Liou J.Y., Shyu K.G. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol. Pharmacol. 2004, 66:612-619.
8. Wang N., Feng Y., Zhu M., Tsang C.M., Man K., Tong Y., Tsao S.W. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J. Cell. Biochem. 2010, 111:1426-1436.
9. Tsang C.M., Cheung Y.C., Lui V.W., Yip Y.L., Zhang G., Lin V.W., Cheung K.C., Feng Y., Tsao S.W. Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer 2013, 13:619.
10. Yi J., Ye X., Wang D., He K., Yang Y., Liu X., Li X. Safety evaluation of main alkaloids from Rhizoma Coptidis. J. Ethnopharmacol. 2013, 145:303-310.
11. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004, 91:1354-1360.
12. Tang Z.Y. Hepatocellular carcinoma - cause, treatment and metastasis. World J. Gastroenterol. WJG 2001, 7:445-454.
13. Fong Z.V., Tanabe K.K. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014, 120:2824-2838.
14. Poon R.T., Ng I.O., Lau C., Yu W.C., Yang Z.F., Fan S.T., Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 2002, 20:1775-1785.
15. Welker M.W., Bechstein W.O., Zeuzem S., Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl. Int. Off. J. Eur. Soc. Organ Transplant. 2013, 26:109-118.
16. Lee T.K., Poon R.T., Yuen A.P., Ling M.T., Wang X.H., Wong Y.C., Guan X.Y., Man K., Tang Z.Y., Fan S.T. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:6910-6919.
17. Kadesch T. Consequences of heteromeric interactions among helix-loop-helix proteins. Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res. 1993, 4:49-55.
18. Ling M.T., Wang X., Zhang X., Wong Y.C. The multiple roles of Id-1 in cancer progression. Differ. Res. Biol. Divers. 2006, 74:481-487.
19. Cheung H.W., Ling M.T., Tsao S.W., Wong Y.C., Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004, 25:881-887.
20. Ling M.T., Wang X., Ouyang X.S., Xu K., Tsao S.W., Wong Y.C. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 2003, 22:4498-4508.
21. Wang Q., Tsao S.W., Fu S., Xue W., Meng X., Feng H., Wong Y.C., Wang X. Overexpression of Id-1 in gastric adenocarcinoma: implication for a novel diagnostic marker. Anticancer Res. 2004, 24:881-886.
22. Li B., Tsao S.W., Li Y.Y., Wang X., Ling M.T., Wong Y.C., He Q.Y., Cheung A.L. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int. J. Cancer 2009, 125:2576-2585.
23. Fong S., Itahana Y., Sumida T., Singh J., Coppe J.P., Liu Y., Richards P.C., Bennington J.L., Lee N.M., Debs R.J., Desprez P.Y. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13543-13548.
24. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K., Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677.
25. Kitano K., Murayama T., Sakamoto M., Nagayama K., Ueno K., Murakawa T., Nakajima J. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur. J. Cardiothorac. Surg. Off. J. Eur. Assoc. Cardiothorac. Surg. 2012, 41:376-382.
26. Li Y., Tang Z.Y., Ye S.L., Liu Y.K., Chen J., Xue Q., Chen J., Gao D.M., Bao W.H. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. WJG 2001, 7:630-636.
27. Ding R., Han S., Lu Y., Guo C., Xie H., Zhang N., Song Z., Cai L., Liu J., Dou K. Overexpressed Id-1 is associated with patient prognosis and HBx expression in hepatitis B virus-related hepatocellular carcinoma. Cancer Biol. Ther. 2010, 10:299-307.
28. Brito A.F., Abrantes A.M., Pinto-Costa C., Gomes A.R., Mamede A.C., Casalta-Lopes J., Goncalves A.C., Sarmento-Ribeiro A.B., Tralhao J.G., Botelho M.F. Hepatocellular carcinoma and chemotherapy: the role of p53. Chemotherapy 2012, 58:381-386.
29. Zhu A.X., Duda D.G., Sahani D.V., Jain R.K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 2011, 8:292-301.
30. Pang R., Poon R.T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006, 242:151-167.
31. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
32. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
33. Lee T.K., Man K., Ling M.T., Wang X.H., Wong Y.C., Lo C.M., Poon R.T., Ng I.O., Fan S.T. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis 2003, 24:1729-1736.